We investigated genetic resistance mechanisms to olaparib53 and niraparib54 in the Ewing sarcoma cell line MHH-ES-1, which harbors an EWSR1 fusion conferring sensitivity to PARP inhibitors55 (Fig. 4a). Here, PARP1 is linked to Ewing sarcoma.